Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3202578 A
Publication typeGrant
Publication dateAug 24, 1965
Filing dateSep 27, 1957
Priority dateSep 27, 1957
Publication numberUS 3202578 A, US 3202578A, US-A-3202578, US3202578 A, US3202578A
InventorsHoward E Parker
Original AssigneeElder Paul B Co
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Polymeric laxative composition and method of using same
US 3202578 A
Images(4)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent 3,252,578 POLYMERIQ LAXriTli/E tJOP/EPGSITTQN AND METHQE) 0F USENG SAME Howard E. Parker, Bryan, @hio, assignor to Paul E. Elder Company, Bryan, (Elsie, a corporation of Ulric N0 Drawing. Filed Sept. 27, 1957, Ser. No. 686,698 13 Claims. (Cl. 167-56} The present invention relates to a therapeutic composition and is more particularly concerned with a composition for use as a fecal softening agent, such composition containing a non-ionic surface active component. The invention further relates to compositions containing other therapeutically active medicaments in addition to the non-ionic component.

Heretofore, a wide variety of therapeutic compositions have been utilized as fecal softening agents. These include various proprietary products and the recently developed softening agents, e.g. dioctyl sodium sulfosuccinate and thiamine dioctyl sulfosuccinate, Some compositions have incorporated other anionic and cationic detergents or surface active compounds, The function of these therapeutic compositions is merely to soften the contents of the lower intestines and to relieve constipation. Such compositions exert a softening effect but do not stimulate peristaltic movement. Consequently, peristaltic stimulants are frequently administered in conjunction with the use of fecal softening agents.

Among the most effective ionic wetting agents reported to date are dioctyl sodium sulfosuccinate (aerosol o.t.) and thiamine dioctyl sulfosuccinate. These compounds, however, have a pronounced obnoxious odor and are very bitter to the taste. Further, the compounds are not readily water-soluble. They are waxy in nature and formulations containing them are difficult to prepare. Further, because of their ionic nature these compounds frequently cause irritation to the skin and they tend to be unstable in the presence of acids and alkalies. In addition, these compounds are precipitated by most metal ions. Thus, it is an object of the present invention to provide a novel composition for use as an orally ingested fecal softening agent.

An additional object of the present invention is to provide a therapeutic composition containing as an active component a compound that is substantially odorless and tasteless, that is stable in the presence of acids and alkalics and that does not readily react with metal ions.

It is a further object of the present invention to provide a therapeutic composition that is readily dispersible in the contents of the stomach and intestines and whose primary active component is substantially soluble in Water at room temperature in all proportions and is itself readily dispersed in the intestinal tract.

Still another object of the present invention is to provide a therapeutic composition in dosage unit form containing a non-ionic surface active agent and having, in addition to fecal softening properties, pronounced effect in reducing blood serum cholesterol content.

These and other objects of the present invention will become apparent to one skilled in the art as the description of the present invention proceeds.

It has now been found that a therapeutic composition can be prepared for use as an orally ingested, fecal softening agent comprising a non-ionic, polyoxyalliylene material, such as a condensation product of ethylene oxide and polyoxypropylene glycol, and a pharmaceutical carrier. Such preferred condensation products are nonionic in character and the preferred products are substantially water-soluble, having molecular weights of between about one thousand and about eleven thousand. The ethylene oxide proportion of the total weight of the 32%,578 Patented Aug. 24, 1965 molecule may vary from as low as about 10 percent to about percent.

The pharmaceutical carrier comprises both solid and liquid materials and the therapeutic composition of the present invention may be packaged in capsule, liquid and tablet form.

The therapeutic composition of the present invention has utility as a fecal softening agent generally. It is useful in relieving constipation, especially constipation induced by the intake of antacids containing aluminum hydroxide and similar compounds. It is useful in the treatment of diverticulosis.

Structurally, the active non-ionic agents in the therapeutic compositions of this invention are unrelated to the active components of the widely used proprietary prodnets and the sulfonated dicarboxylic acid esters, e.g. dioctyl sodium sulfosuccinate (bis(2-ethylhexyl)sodium sulfosuccinate). The compounds employed in the compo sitions of the present invention are basically resin or plastic materials and are more specifically block-polymers having surface active properties. These resins are linear in nature and contain both hydrophilic and hydrophobic units. The term, non-ionic, surface active polyoxyalkylene materials is used in the specification and claims to denote these resinous compositions containing both hydrophilic and hydrophobic units. The term includes both the fatty acid esters or fatty alcohol ether types of non-ionic surfactants. Generally these are condensation products of alkylene oxides, such as ethylene or propylene oxide, and polyols, such as the glycols, sorbitols, polyoxyalkylene glycols and the like. In the preferred compositions, for example, the hydrophobic or water-insoluble portion of the polymers are polyoxypropylene compounds whereas the hydrophilic portions of the polymers are polyoxyethylene compounds. These preferred resins can be represented structurally as follows:

wherein the (C T-1 0) represents the polyoxypropylene hydrophobic base component and the Ho c H,0 and (C H O) H represent the polyoxyethylene hydrophilic constituents. The molecular weight of the preferred polymers useful in the compositions of the present invention may be as low as about 1609 and as high as about 11,000 and wherein the polyoxyethylene portion of the polymer may vary from as little as 10 percent to as high as 90 percent, respectively. The higher the polyoxyethylene percentage, the more water-soluble becomes the total molecule or polymer. Thus, the substantially water-soluble polymers in the molecular weight range of between about five and about eleven thousand are preferred. The resins through this molecular weight range may be liquids, pastes and even crystalline flakes or powders. The preferred resin embodiment is a polymer having a molecular weight of about seven thousand five hundred, an ethylene oxide content of between about eighty and ninety percent by weight of the total molecule, and a melting point of 5l54 degrees centigrade. The polymer is substantially water-soluble and is readily compatible with the selected pharmaceutical carriers.

These resin compounds have excellent surface active properties, including good wetting, and exhibit low toxicity, especially when compared with other surface active agents or detergents. These compounds are stable to acids, alkalies and metal ions, due in part to their nonionic character. The polymers, especially in the higher molecular weight ranges, are virtually odorless and tasteless. These properties are especially valuable since there is less tendency for them to react with vitamins, minerals, enzymes and the like in the stomach and intestines than for conventional anionic and cationic agents. Because these polymers are non-ionic and are virtually neutral are operative.

.3 in pH they are less irritating to the skin than the more reactive ionic wetting agents.

In FIGURE 1 below are comparative data showing the stability of the resinous compounds of the present invention in various media with which they are associated in use. Comparison of a preferred member of this resin series has been made with dioctyl sodium sulfosuccinate, the most effective of the known fecal softening ionic wetting agents. Equal volume portions cos. each) of the conventional ionic wetting agent and the non-ionic polyoxypropylene glycol-ethylene oxide condensation product, respectively, were compared with equal volumes of the selected test material.

FIGURE 1 d pounds. When the dosage unit form is capsule or tablet, 250 milligrams of the selected non-ionic agent produces a very desirable dosage. Preferred embodiments of other dosage units are illustrated in the examples.

In use, from one to six or more dosage units may be used daily by oral ingestion. In addition to the primary action of wetting or softening of the stool, administration of the therapeutic composition has been demonstrated clinically to cause stimulation of the gut and, hence, to initiate peristalsis in some patients. In such instances, it has not been necessary to co-administer a peristaltic stimulant.

These novel compositions are effective in preventing Polyoxypropylene Material tested Dioctyl Sodium Sulfosucci glycol-ethylene oxide mate, 1% condensation product (Pluronic F458), 1%

2% NaOH Haze-Cloudy Clear. 2% H01- Slight Haze Do. Artificial G astric Juice" Haze-Cloudy Do. 2% Calcium Chloride Haze-Cloudy precipitatelnu D0. 0.2% Calcium Chloride. do Do. 0.1% Supernatant Calcium Shght Haze Do.

Citrate. Artificial Intestinal Juice do Do. Atropine Sulfate Heavy preeipitat Do. Sodium Salicylate Slight precipitate. Do. Sod. Pentobarbital.-. Very slight haze"--. Do. Vitamin B Heavy precipitate Do. Vitamin C Clear Do. 1% Ferrous Sulfate Precipitate Do. 1% Ferrous Gluconate 0 D0. NaCl Precipitate (settles out and D0.

clears). Liver Concentrate Solution Precipitate Do.

(filtered). 1% Phenol Clear Preclpitate. Extract of Hog Bile do Clear. Caffeinerln Do.

In further testing with non-ionic compositions, polyoxyethylene sorbitan monooleate (Tween 8O)- 1 percent, was tested against vitamin B1, artificial gastric juice, hydrochloric acid2 percent, atropine sulfate dilution 1 percent, ferrous gluconate 'solutionl percent, phenol- 1 percent, Dl-amphetamine sulfatel percent, and pyrilamine maleatel percent. Turbidity was not produced.

In like manner, another polyoxyalkylene material (Triton X-lOO) was tested under comparable conditions and produced slight turbidity only with the one percent phenol solution. Thus, both of these latter compositions However, both of these are liquids with a somewhat bitter taste and are thus not'preferred embodiments of the present invention.

Several of these preferred non-ionic agents are commercially available under the trademark, Pluronic (Wyandotte Chemical Company). Others have been synthesized by controlled reaction of the appropriate polyoxypropylene base, formed by condensation of propylene oxide with propylene glycol, with ethylene oxide. For example, the non-ionic polyalkylene glycol others are available as Tergitols (Carbide and Carbon Chemicals Company), such as the Tergitol XD, a solid surfactant that is stable in the presence of most of the materials listed above.

In preparing the therapeutic compositions of the present invention, non-toxic pharmaceutical carriers or diluents are employed, such as corn starch, distilled water, powdered milk sugar, gum acacia, talc, glycerin and the like. Flavoring agents, viscosity regulators, excipients and lubricants may be employed, Where desired. The carrier chosen will depend on the ultimate form of the therapeuearth metals.

is the magnesium ion.

dehydration of waste material in the colon. Where use of antacids containing aluminum hydroxide or other gels or bulking agents has caused severe dehydration of the fecal matter, the compositions have been found useful in softening the compacted material. Pronounced symptomatic relief in persons having diverticulitis of the colon has been observed upon administration of the therapeutic compositions.

Unexpectedly, it has beenfound that the compositions of the present invention may be successfully employed in some instances in the treatment of hypercholesteremic conditions. For example, it has been demonstrated clinically that the orally ingested therapeutic compositions caused a reduction in blood serum cholesterol content in persons showing elevated cholesterol, i.e. 270-280 milligrams of cholesterol per milliliters of blood serum. Substantial reductions were observed without any change in the diet of the patient. While the compositions illustrated in Examples 1 and 2 have been found operable for this purpose, the compositions of Examples 3 and 5, respectively, may yield better results, apparently due in part to the inclusion of compounds containing alkaline In general, compounds containing elements from the Group II of the periodic classification of the elements are preferably incorporated with the nonionic polymeric agent. in their outer shells, such as beryllium, strontium, and magnesium, are preferred. The preferred embodiment Where the use of these novel therapeutic compositions in the treatment of hypercholesteremia is indicated, a compound selected from the group consisting of non-toxic unsaturated oils and um saturated oil fatty acids may be incorporated, if desired- Metals containing two electrons The following examples illustrate the compositions of the present invention:

Example 1.--Capsul.e form (per capsule) Nonionic agent (Pluronic F-68; mo lecular weight about 7500; MP. 5l-54 degrees C.; ethylene oxide content 8090 percent) 250 milligrams. Dried corn starch 138.8 milligrams (i.e. sufficiengt corn starch to maintain a six grain capsule).

Example 2.Lfquid form (per 5 cc. dosage unit) Non-ionic agent (Pluronic 1 -68) milligrams 250 Distilled water cc. 3.0 Glycerin cc. 0.50

Flavoring agent, q.s.

In preparation, the non-ionic agent was dispersed easily in the aqueous components.

In like manner, another non-ionic agent (Pluronic L-62), being in liquid form and having a molecular weight of about 2000, can be utilized in place of the above non-ionic agent.

Example 3.Tablet form (per tablet) Nonionic agent (Pluronic F-6S) milligrams 250 Milk sugar do 350 Gum acacia (gum arabic) do 50 Magnesium stearate do 1.0

Starch, q.s. to Weight.

In preparation the above components were admixed thoroughly and tableted in a conventional tablet machine.

Example 4'.Capsule (per capsule) Non-ionic agent (Pluronic P45)- molecular weight about 3,500 milligrams. Dried corn starch 378 milligrams (i.e. sufiicient corn starch to maintain a six grain capsule) Example 5.Liquid emulsion (per 50 cc.)

Non-ionic agent gram 1.0 Satlron oil (or linoleic acid) cc. 20 Distilled water, q.s. ad.

Flavoring agent min. 5

Example 6.-Capsule (per capsule) Non-ionic agent (Pluronic F-68) 250 milligrams.

Magnesium stearate 10 milligrams.

Dried corn starch 128.8 milligrams (i.e. sufficient corn starch to maintain a six grain capsule).

Example 7.Bullc type laxative preparation (per teaspoon dosage) Psyllium seed huslrs grams 3.5 Gum karaya do 0.5 Non-ionic agent (Pluronic 1 -68) milligrams 250 Powdered dextrose grams 0.75

The bulk laxative was produced by finely milling the above components and subsequently Wetting the admixture to produce granules. (Alternatively, the preparation has been made by dissolving the non-ionic agent in the water utilized to produce the granules.)

Example 8.Bulk type laxative preparation (per' teaspoonful dosage) Psyllium seed husks (aqueous extractive) grams 2.0

Powdered anhydrous dextrose do 2.0 Non-ionic agent (Pluronic F-68) milligrams 300 Example 9.Bzrlk type laxative preparation (per teaspoonful dosage) Psyllium seed husks grams 4.5 Non-ionic agent (Pluronie F68) milligrams 350 Example 10.Laxative (per capsule) Milligrams Non-ionic agent (Pluronic P-68) 250 Danthron 5O Dried corn starch 138.8

This composition was prepared in the manner of Example l.

Cascara Sagrada granular extract in the amount of 100 milligrams has been substituted for the Danthrone in this composition.

In addition, powdered ox or hog bile in the amount of about 100 milligrams may be added to the above composition.

Example 11.Laxative (per capsule) Milligrams Desiccated hog bile (equivalent to about 2.5 cc. of

fresh hog bile) 325 Non-ionic agent (Pluronie 1 -68) 250 Example 12.-Gastric antacid preparation (per tablet) Aluminum hydroxide gel (dried) grains l0 Non-ionic agent (Pluron-ic 1 -68) milligrams 100 The amount of non-ionic agent has been varied from between about 50 and 250 milligrams per 10 grain antacid tablet.

In practice, the compositions of Examples 1 to 12, inclusive, maybe administered daily in from one to as many as six or more of the unit doses set forth above.

in like manner, other non-ionic, surface active polyoxyalkylene materials, especially the condensation products of ethylene oxide and polyoxypropylene glycol having molecular weights of between about one and about eleven thousand and ethylene oxide contents of between about 10 and percent, respectively, by weight, have been successfully substituted for the non-ionic agents of the above examples. Also, other alkaline earth compounds, wherein the alkaline earth metal per se has two electrons in their outer shells, such as beryllium, strontium, barium, magnesium, and the like, have been used successfully in place of the magnesium compounds set forth in the above examples. Among the preferred fatty acids useful in the above compositions are linoleic and arachidonic.

While the therapeutic compositions of the present invention have been described with primary reference to dosage unit form as fecal softening agents, the active nonioniccompositions can be administered concomitantly with other medicaments, especially peristaltic stimulants and the like, wherein such agents continue to function as fecal softening promoters in the presence of the other med-icaments. Examples 7 to 11, illustrate the combined use of the non-ionic composition in admixture with other components having therapeutic activity as laxatives and choleretics. Example 12 above illustrates the use of the preferred compositions with gastric antacid preparations, wherein the non-ionic agent continues to function as a fecal softening compound. Likewise, in the preparation of baby foods, the compounds of the present invention have been incorporated as fecal softening material. Thus, the present invention further contemplates these therapeutic compositions which comprise as their essentially active components other medicaments or therapeutics, as well as the non-ionic, surface active, fecal softening polyoxyalkylene materials.

The present invention also includes a method for preparing a composition exhibiting fecal softening properties and which generally comprises the admixing of a non- .ionic, surface active polyoxyalkylene material and a pharmaceutical carrier.

As noted in the specification, the compositions intended are fecal softening compositions and methods for their use and are applied to persons, patients and babies (see column 4, line 43, column 7, line 11, etc.) and are clearly intended for human therapy. Thus, these compositions of the present invention are orally administered to humans to soften the fecal matter as above discussed.

Other modifications can be made in the compositions and methods of the present invention without departing from the spirit or the scope thereof and it is to be understood that such modifications are included Within the scope of the appended'elaims.

I claim:

1. The method for treating constipation in humans comprising orally administering an effective amount of a composition consisting essentially of a compound'h-aving the formula:

wherein the moi-weight of the (C H O) groups is to 90% of the polymer and b is an integer between about 25-32.

2. The method of softening human fecal matter which comprises: orally administering a dosage unit of a composition comprising the polymer of the formula:

wherein a and c comprise between about ten to about ninety percent by weight of the polymer and wherein the polymer has a molecular weight between about one thousand and about eleven thousand, the composition containing that amount of polymer per dosage unit necessary to induce softening of the fecal matter and thus to facilitate evacuation of the fecal matter.

3. Claim 2 wherein the composition contains between about ten and about three hundred milligrams of the polyabout ten and about three hundred milligrams of polymer per dosage unit and in addition the composition contains a pharmaceutical carrier.

7. Claim 2 wherein in addition the composition contains a pharmaceutical carrier.

8. A composition in dosage unit form for use as an orally ingested human fecal softener which comprises:

(a) a polymer of the formula:

wherein a and c comprise between about ten to about ninety percent by weight of the polymer and wherein the polymer has a molecular weight between about one thousand and about eleven thousand; and

(b) a peristalsis stimulating laxative, the composition containing that amount of polymer per dosage unit necessary to induce softening of the fecal matter and thus to facilitate evacuation of the fecal matter.

9. Claim 8 wherein the peristalsis stimulating laxative is psyllium.

10. Claim 8 wherein the peristalsis stimulative laxative is bile.

1 1. Claim 8 wherein the composition contains between about ten and about three hundred milligrams of polymer per dosage unit. l

12. Claim 8 wherein the composition contains between about ten and about three hundred milligrams of polymer per dosage unit, wherein the polymer has a molecular weight of about seven thousand five hundred and a melting point of about fifty-one to fifty-four degrees centigrade and wherein a and c comprise about eighty to ninety percent by weight of the polymer.

13. Claim 8 wherein in addition the composition contains a pharmaceutical carrier.

References Cited by the Examiner JULIAN S. LEVITT, Primar y Examiner.

MORRIS O. WOLK, WILLIAM B. KNIGHT,

- Examiners.

Non-Patent Citations
Reference
1 *None
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3401218 *Jun 9, 1967Sep 10, 1968Smith Kline French LabMethod of producing gastrointestinal spasmolytic activity with polyoxypropylene-polyoxyethylene polymers
US3867521 *Feb 7, 1972Feb 18, 1975Scherer Corp R PMethod for absorption of drugs
US5229117 *Sep 30, 1991Jul 20, 1993The Procter & Gamble CompanyMethods and apparatus for sanitizing materials utilizing superheated steam
US5710183 *Jul 14, 1995Jan 20, 1998Halow; George M.And optionally a wetting aagent and gas reducing agent; improved bowel function
US5912011 *Mar 8, 1995Jun 15, 1999R. P. Scherer CorporationSolvent system to be enclosed in capsules
US7687075Nov 16, 2004Mar 30, 2010Salix Pharmaceuticals, Ltd.Colonic purgative composition with soluble binding agent
US7718197Mar 13, 2008May 18, 2010Salix Pharmaceuticals, Ltd.Colonic purgative composition with soluble binding agent
US8507009Jan 20, 2010Aug 13, 2013Salix Pharmaceuticals, Inc.Colonic purgative composition with soluble binding agent
USRE32811 *Jun 3, 1986Dec 27, 1988S. C. Johnson & Son, Inc.Easily dispersible dietary fiber product and method for producing the same
EP0464274A1 *Jun 6, 1990Jan 8, 1992GŁnter StephanSoft gelatin capsule
EP0496705A1 *Jan 23, 1992Jul 29, 1992Emil Flachsmann AGComposition especially adapted for encapsulation in a solid shell and process for preparing same
Classifications
U.S. Classification424/78.1, 424/738
International ClassificationA61K36/68, A61K31/77, A61K35/413, C08L71/02
Cooperative ClassificationA61K35/413, A61K31/77, A61K36/68, C08L71/02
European ClassificationA61K36/68, A61K35/413, C08L71/02, A61K31/77